AksharChem swings to ₹13.3 Cr standalone profit in Q2 FY27 as revenue surges 80% YoY
revenue +79.71% · margins expanding
₹160.48 Cr
+79.71% YoY
₹13.32 Cr
8.3%
+9.8pp YoY
₹16.58
AksharChem (India) reported standalone revenue from operations of ₹160.48 Cr for Q2 FY27 (quarter ended September 30, 2026), up 79.7% YoY from ₹89.30 Cr a year ago and up 13.9% QoQ from ₹140.87 Cr in Q1 FY27. Standalone PAT came in at ₹13.32 Cr, reversing a ₹1.37 Cr net loss in Q2 FY26 — a clear YoY turnaround. That year-ago comparison is itself flattered: Q2 FY26 carried a ₹1.70 Cr insurance-claim exceptional gain (final settlement of a May 2024 fire-damage claim at the company's VS Plant), so the underlying year-ago loss was closer to ₹3.07 Cr — making the swing to this quarter's profit sharper on a like-for-like basis. The current quarter carried no exceptional items.
Q2 FY-2027 vs prior quarters
Net profit margin was 8.3% this quarter, down from 10.8% in Q1 FY27 but up sharply from -1.5% a year ago. PAT also slipped 12.4% QoQ (₹13.32 Cr vs ₹15.21 Cr) even as revenue grew: operating profit (PBT before exceptional items, with finance cost and depreciation added back) eased to ₹21.01 Cr (13.1% of revenue) from ₹22.65 Cr (16.1%) in Q1 FY27. The main swing factor was the "changes in inventories" line, which moved from a ₹20.97 Cr credit in Q1 FY27 (inventory build) to a ₹10.33 Cr charge in Q2 FY27 (inventory drawdown) — a roughly ₹31 Cr adverse swing that outpaced the ₹19.6 Cr QoQ revenue gain, even though raw-material cost as a share of revenue actually eased to 52.6% from 60.0% in Q1.
The stock went into the print at ₹412.25, up 3.8% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters; revenue is at a 6-quarter high.
There is no analyst/street coverage of this small-cap stock (Tipranks and Simply Wall St show no consensus EPS estimates), so a vs-street read isn't possible, and the company has issued no formal forward guidance in its filings or press commentary. The filing itself carries no separate management commentary beyond standard notes confirming the single-segment "Chemical Business" classification and reiterating the fire-claim history. H1 FY27 cumulative PAT of ₹28.53 Cr has already reversed both the ₹0.66 Cr H1 FY26 loss and the ₹0.44 Cr full-year FY26 net loss the company posted in March 2026. The same board meeting also approved re-designating and re-appointing Munjal M. Jaykrishna as Managing Director & CEO and renewed Sachin M. Jaykrishna's term as Whole-Time Director, both for three years — a governance-continuity move alongside the results, with no direct bearing on the reported numbers.
W1
Whether the Q2 FY27 operating-profit margin dip to ~13.1% (from 16.1% in Q1 FY27) was a one-quarter inventory-timing effect or a trend — Q3 FY27 margin is the marker
W2
79.7% YoY revenue growth this quarter is against an unusually weak Q2 FY26 base (₹89.30 Cr) — watch whether growth holds against a tougher base in Q3 FY27
W3
H1 FY27 PAT of ₹28.53 Cr has already erased FY26's full-year ₹0.44 Cr net loss — full-year FY27 profitability trajectory to confirm in H2
Informational and educational content only. Not investment advice.